{"id":1535,"date":"2023-02-09T17:52:11","date_gmt":"2023-02-09T17:52:11","guid":{"rendered":"https:\/\/tradersontrend.com\/?p=1535"},"modified":"2023-02-09T17:52:11","modified_gmt":"2023-02-09T17:52:11","slug":"covid-crisis-may-be-over-but-theres-plenty-in-store-for-these-healthcare-stocks","status":"publish","type":"post","link":"https:\/\/tradersontrend.com\/h\/2023\/02\/09\/covid-crisis-may-be-over-but-theres-plenty-in-store-for-these-healthcare-stocks\/","title":{"rendered":"Covid Crisis May be Over, but There\u2019s Plenty in Store for These Healthcare Stocks!"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"1535\" class=\"elementor elementor-1535\" data-elementor-post-type=\"post\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-6fd8aa96 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"6fd8aa96\" data-element_type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-15a0844a\" data-id=\"15a0844a\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-781daab9 elementor-widget elementor-widget-text-editor\" data-id=\"781daab9\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t<style>\/*! elementor - v3.21.0 - 26-05-2024 *\/\n.elementor-widget-text-editor.elementor-drop-cap-view-stacked .elementor-drop-cap{background-color:#69727d;color:#fff}.elementor-widget-text-editor.elementor-drop-cap-view-framed .elementor-drop-cap{color:#69727d;border:3px solid;background-color:transparent}.elementor-widget-text-editor:not(.elementor-drop-cap-view-default) .elementor-drop-cap{margin-top:8px}.elementor-widget-text-editor:not(.elementor-drop-cap-view-default) .elementor-drop-cap-letter{width:1em;height:1em}.elementor-widget-text-editor .elementor-drop-cap{float:left;text-align:center;line-height:1;font-size:50px}.elementor-widget-text-editor .elementor-drop-cap-letter{display:inline-block}<\/style>\t\t\t\t<p><span style=\"font-weight: 400;\">As the crisis from the COVID-19 pandemic subsides, and the number of casualties decreases, many parts across the world are breathing a collective sigh of relief. <br \/><br \/>However, the effects of the pandemic will continue to be felt for a long time, possibly for decades. <br \/><br \/><\/span><span style=\"font-family: inherit;\">The <\/span><a style=\"font-family: inherit;\" href=\"https:\/\/www.healthaffairs.org\/content\/forefront\/vaccine-development-after-covid-19-pandemic-programs-and-policies-ready-embrace\">healthcare industry is among the most significantly impacted by the pandemic<\/a><span style=\"font-family: inherit;\">, and is undergoing a rapid transformation. <br \/><br \/>Also, it has accelerated the need for more innovative and effective healthcare solutions, bringing new opportunities to make money.<br \/><br \/><\/span><span style=\"font-weight: 400;\">And if high-interest rates persist and cause a recession in the U.S. economy, as forecasted by numerous experts, they believe that the healthcare sector has the potential to perform well again this year.<br \/><br \/><\/span><span style=\"font-weight: 400;\">Regardless of economic conditions, people tend to regularly visit their doctors and take their prescribed medications. <br \/><br \/>Just because there\u2019s a recession doesn\u2019t mean that people will stop taking care of their health, do they?\u00a0<br \/><br \/><\/span><span style=\"font-weight: 400;\">This time around, the <a href=\"https:\/\/publichealth.uic.edu\/news-stories\/study-finds-healthcare-sector-largely-immune-to-economic-downswings\/\">healthcare sector may be in an even stronger position compared to previous recessions<\/a>, due to the fact that a larger portion of Americans now has healthcare coverage through government-sponsored plans. <br \/><br \/>This should make healthcare spending less affected by the state of the economy.<br \/><br \/><\/span><span style=\"font-weight: 400;\">Can\u2019t blame these companies though, if they are wanting more people to need medical help!\u00a0<br \/><br \/><\/span><span style=\"font-weight: 400;\">And with most stocks in the healthcare sector down for 2023, and not joining the bullish move of the general market, healthcare investors might just have been given a perfect opportunity to buy.<br \/><br \/><\/span><span style=\"font-weight: 400;\">For this week, I have several stocks in the healthcare industry that are well-positioned to perform in a post-Covid environment.\u00a0<br \/><br \/><\/span><span style=\"font-weight: 400;\">Let\u2019s take a look!<br \/><br \/><\/span><b style=\"font-size: 24.5px; font-family: inherit;\">Pfizer, Banking on Expansion Across the Board<br \/><br \/><\/b><span style=\"font-family: inherit;\">Pfizer is expected to experience robust sales growth, excluding COVID-related products, due to the introduction of new offerings. <br \/><br \/>The company believes that the products it launches in the first half of 2024 will contribute an additional $20 billion in annual revenue, adjusted for risk, by 2030, surpassing the anticipated decline in sales from the loss of exclusivity for older products.\u00a0<br \/><br \/><\/span><span style=\"font-weight: 400;\">With its substantial cash reserve and robust cash flow, Pfizer intends to fund additional business development deals, which are expected to generate an additional $25 billion in annual revenue by 2030. <br \/><br \/>The company has already made considerable progress toward this goal, having acquired Arena, Biohaven, Global Blood Therapeutics, and ReViral and estimating that these acquisitions will bring in an additional $10.5 billion in annual sales by 2030.<br \/><br \/><\/span><span style=\"font-weight: 400;\">Furthermore, <a href=\"https:\/\/www.fiercepharma.com\/pharma\/pfizer-sees-covid-19-vaccine-sales-falling-64-2023-paxlovid-declining-58\">Pfizer&#8217;s new products may surpass sales projections<\/a> and its pipeline could yield more successful products than originally forecasted. <br \/><br \/>The company may also engage in further acquisitions or licensing agreements that drive its growth beyond investor expectations. <br \/><br \/>Additionally, COVID-19 could potentially generate greater long-term revenue and profits than is currently anticipated.<br \/><br \/><\/span><span style=\"font-weight: 400;\">In my opinion, Pfizer has the potential to exceed expectations in the coming years, especially with its very compelling dividend yield of 3.73%, which compensates investors while they await the company&#8217;s return to growth.<br \/><br \/><\/span><b style=\"font-size: 24.5px; font-family: inherit;\">Gilead Sciences<br \/><br \/><\/b><a style=\"font-family: inherit;\" href=\"https:\/\/www.bizjournals.com\/sanfrancisco\/news\/2023\/02\/06\/gilead-sciences-ceo-on-delivering-transformative-m.html\">Gilead Sciences was one of the first companies to release a treatment for COVID-19<\/a><span style=\"font-family: inherit;\">, receiving emergency approval for its antiviral drug, Remdesivir, in May 2020. <br \/><br \/>The drug, now known as Veklury, is still being used, though its usage has declined.<br \/><br \/><\/span><span style=\"font-weight: 400;\">Gilead Sciences is well-known for its dominance in the HIV drug market, but in recent years, its revenue has been sustained primarily by its COVID-19 treatment, Veklury. <br \/><br \/>The company faced regulatory challenges and was unable to launch some products, but Veklury kept its financial performance afloat.<br \/><br \/><\/span><span style=\"font-weight: 400;\">Due to declining COVID hospitalizations and the increasing availability of oral antiviral drugs like Pfizer&#8217;s Paxlovid, sales of Gilead Sciences&#8217; Veklury, which is delivered through intravenous infusion, are starting to face pressure.<br \/><br \/><\/span><span style=\"font-weight: 400;\">Despite this, the company&#8217;s pipeline, including its oncology and HIV units, is expected to continue advancing this year with multiple phase 2 and phase 3 studies underway. <br \/><br \/>In the long term, the company should secure new approvals and label expansions, just as it has in the past. Once the impact of Veklury on its financial results fades, Gilead&#8217;s top-line growth rate is likely to improve.<br \/><br \/><\/span><span style=\"font-weight: 400;\">Gilead Sciences&#8217; dependable dividend is yet another reason to invest in its shares. <br \/><br \/>The biotech company recently announced a 2.7% increase in its dividend, a move it has made regularly in the past. <br \/><br \/>The stock boasts a yield of 3.48%, which is significantly higher than the average yield of 1.74% offered by the S&amp;P 500.<br \/><br \/><\/span><span style=\"font-family: inherit;\">In conclusion, Gilead Sciences is a well-established company with a strong business and a reliable dividend, making it an attractive option for long-term investors.<br \/><br \/><\/span><b style=\"font-size: 24.5px; font-family: inherit;\">Merck<br \/><br \/><\/b><span style=\"font-family: inherit;\">Pharmaceutical giant <\/span><a style=\"font-family: inherit;\" href=\"https:\/\/www.merckgroup.com\/press-releases\/2020\/apr\/en\/Boost-to-viral-vector-gene-therapy-manufacuturing-EN.pdf\">Merck boasts a diverse range of products across multiple therapeutic areas.<\/a><span style=\"font-family: inherit;\"> <br \/><br \/>Although its cancer drug Keytruda is the company&#8217;s most well-known and valuable asset, Merck also has other significant offerings in its vaccine and animal health divisions.<br \/><br \/><\/span><span style=\"font-family: inherit;\">The drugmaker&#8217;s vaccine and animal healthcare segments are projected to provide robust financial results for the rest of the decade, reducing the risk of a significant decline in annual revenue in the next five years.<br \/><br \/><\/span><span style=\"font-family: inherit;\">With a focus on earning new approvals, Merck is actively pursuing opportunities. <br \/><br \/>One promising candidate is Sotatercept, a potential treatment for pulmonary arterial hypertension. <br \/><br \/>The company acquired this candidate through its acquisition of Acceleron Pharma in 2021. <br \/><br \/><\/span><a style=\"font-family: inherit;\" href=\"https:\/\/www.fiercepharma.com\/pharma\/merck-kgaa-will-focus-big-3-business-sectors-consider-large-scale-acquisitions-2023-onwards\">Merck is also expected to make a midsize acquisition to enhance its long-term growth potential<\/a><span style=\"font-family: inherit;\">. Although a deal has yet to be made, the company is expected to make a significant investment within the next two years.\u00a0<br \/><br \/><\/span><span style=\"font-weight: 400;\">With strong free cash flow, Merck is capable of executing a midsize transaction sometime in the future. And don\u2019t forget about its solid dividend program, which makes it a strong choice for investors seeking growth, value, and a reliable income stream.<br \/><br \/><\/span><b style=\"font-size: 24.5px; font-family: inherit;\">Still, Don\u2019t Count Out Covid Just Yet<br \/><br \/><\/b><span style=\"font-family: inherit;\">The healthcare industry had a rough beginning in 2023, as concerns mounted over a resurgence of the coronavirus. <br \/><br \/>It&#8217;s important to note that although the virus has become less of a threat in recent times, the appearance of a new subvariant of the deadly Omicron strain, and the possibility of additional mutations in the future cannot be ignored.<br \/><br \/><\/span><span style=\"font-family: inherit;\">Despite the current concerns about a resurgence of COVID-19, the healthcare industry has undergone a tremendous amount of innovation in the past two years, making it a compelling option for investors. <br \/><br \/><\/span><span style=\"font-family: inherit;\">With billions being invested in areas with high growth potential such as infectious diseases, cancer, virology, and neurological diseases, the healthcare and biotech sectors are expected to provide long-term returns for those who invest.<br \/><br \/><\/span><span style=\"font-weight: 400;\">Still, healthcare investors who are looking for quick gains may need to be patient.<\/span> <span style=\"font-weight: 400;\">Just make sure you keep yourself healthy while waiting!<\/span><\/p><p><em>For More Stocks And Investment Related News, Click <a href=\"https:\/\/tradersontrend.com\/\">Here<\/a>.<\/em><\/p><p>\u00a0<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>As the crisis from the COVID-19 pandemic subsides, and the number of casualties decreases, many parts across the world are breathing a collective sigh of relief. However, the effects of the pandemic will continue to be felt for a long time, possibly for decades. The healthcare industry is among the most significantly impacted by the&#8230;<\/p>\n","protected":false},"author":1,"featured_media":1536,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[148,293,456,574],"class_list":["post-1535","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-newsletter","tag-covid-crisis","tag-healthcare","tag-pharmaceuticals","tag-stocks-and-investment-news"],"_links":{"self":[{"href":"https:\/\/tradersontrend.com\/h\/wp-json\/wp\/v2\/posts\/1535","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tradersontrend.com\/h\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/tradersontrend.com\/h\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/tradersontrend.com\/h\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/tradersontrend.com\/h\/wp-json\/wp\/v2\/comments?post=1535"}],"version-history":[{"count":0,"href":"https:\/\/tradersontrend.com\/h\/wp-json\/wp\/v2\/posts\/1535\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/tradersontrend.com\/h\/wp-json\/wp\/v2\/media\/1536"}],"wp:attachment":[{"href":"https:\/\/tradersontrend.com\/h\/wp-json\/wp\/v2\/media?parent=1535"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/tradersontrend.com\/h\/wp-json\/wp\/v2\/categories?post=1535"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/tradersontrend.com\/h\/wp-json\/wp\/v2\/tags?post=1535"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}